| ASPsiDb_ID | Mutant allele/ASP-siRNA | Mutant efficacy (%) |
Wild efficacy (%) |
Percentage discrimination (%) |
Gene | Disease | Analysis | Pubmed ID |
|---|---|---|---|---|---|---|---|---|
| ASPsiDb_ID | Mutant allele/ASP-siRNA | Mutant efficacy (%) |
Wild efficacy (%) |
Percentage discrimination (%) |
Gene | Disease | Analysis | Pubmed ID |
| aspsirna0652 | CACACCCUAUUCGGCUGCC GUGUGGGAUAAGCCGACGG |
55 | 5 | 50 | Potasium channel voltage-gated subfamily h member 2(KCNH2) | Long QT Syndrome (LQTS) | 
|
|
| aspsirna0653 | ACCCUAUUCGGCUGCCUUC UGGGAUAAGCCGACGGAAG |
48 | 10 | 38 | Potasium channel voltage-gated subfamily h member 2(KCNH2) | Long QT Syndrome (LQTS) |
|
|
| aspsirna0654 | CCUAUUCGGCUGCCUUCCU GGAUAAGCCGACGGAAGGA |
62 | 15 | 47 | Potasium channel voltage-gated subfamily h member 2(KCNH2) | Long QT Syndrome (LQTS) |
|
|
| aspsirna0655 | CUAUUCGGCUGCCUUCCUG GAUAAGCCGACGGAAGGAC |
10 | 78 | -68 | Potasium channel voltage-gated subfamily h member 2(KCNH2) | Long QT Syndrome (LQTS) |
|